Risk-adapted chemotherapy in childhood medulloblastoma (Q37873471)

24 August 2017

1 reference

title

Risk-adapted chemotherapy in childhood medulloblastoma (English)

1 reference

24 August 2017

0 references

1 reference

1

Ali Varan

1 reference

24 August 2017

1 May 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

1 reference

24 August 2017

11

1 reference

24 August 2017

5

1 reference

24 August 2017

771-780

1 reference

Medulloblastoma in children: a 32-year experience from a single institution.

24 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Chemoradiotherapy for brain tumors: current status and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma in childhood: new biological advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma and supratentorial primitive neuroectodermal tumors: an institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma: present concepts of stratification into risk groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

A review of the factors influencing the prognosis of medulloblastoma. The importance of cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Prognostic factors for medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma. A review of the LDS hospital experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

MOPP chemotherapy without irradiation as primary postsurgical therapy for brain tumors in infants and young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Carboplatin in childhood brain tumors. A Children's Cancer Study Group Phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Pediatric medulloblastoma: toxicity of current treatment and potential role of protontherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Prospective randomised trial of chemotherapy given before radiotherapy in childhood medulloblastoma. International Society of Paediatric Oncology (SIOP) and the (German) Society of Paediatric Oncology (GPO): SIOP II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian Pediatric Brain Tumor Consortium Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

The therapy of infantile malignant brain tumors: current status?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Postoperative chemotherapy in children less than 4 years of age with malignant brain tumors: promising initial response to a VETOPEC-based regimen. A Study of the Australian and New Zealand Children's Cancer Study Group (ANZCCSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Outcome of children less than three years old at diagnosis with non-metastatic medulloblastoma treated with chemotherapy on the "Head Start" I and II protocols.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Central nervous system tumors in patients under three years of age: treatment results of a single institute.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Survival of children under 3 years old with medulloblastoma: a study from the Mexican Cooperative Group for Childhood Malignancies (AMOHP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Medulloblastoma variants: age-dependent occurrence and relation to Gorlin syndrome--a new clinical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

High-dose busulfan and thiotepa followed by autologous stem cell transplantation (ASCT) in previously irradiated medulloblastoma patients: high toxicity and lack of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

High-dose carboplatin, thiotepa, and etoposide with autologous stem cell rescue for patients with previously irradiated recurrent medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.222

21 January 2018

Identifiers

DOI

10.1586/ERA.10.222

1 reference

24 August 2017

1 reference

PubMed ID

21554052